Revolutionary Advances in Spinal Fusion
Theradaptive, an innovative clinical-stage biologics company, has made strides in the field of spinal surgery with its groundbreaking product, OsteoAdapt SP. Recently, the company announced a peer-reviewed publication detailing a preclinical spinal fusion study which showcased the capabilities of OsteoAdapt SP in enhancing bone formation and improving surgical outcomes.
Significant Findings from the Study
The study involved a large animal model demonstrating that OsteoAdapt SP exhibits more effective and rapid bone formation compared to the traditional gold standard, autograft. It highlights the safety and efficacy of AMP2, the engineered protein at the core of OsteoAdapt SP, in preparation for ongoing human studies in clinical trials.
Overview of OsteoAdapt SP
OsteoAdapt SP is an investigational therapeutic specifically designed for patients suffering from degenerative disc disease. This condition leads to the deterioration of spinal joints, resulting in significant pain and functional limitations. The product functions by utilizing AMP2™, a modified variant of the potent bone-forming growth factor BMP-2, alongside a synthetic bone graft. The innovative design of OsteoAdapt SP not only retains the therapeutic benefits of BMP-2 but also minimizes potential side effects associated with traditional BMP-2 treatments.
Study Design and Key Outcomes
The preclinical study was meticulously designed to evaluate the effectiveness of OsteoAdapt SP compared to traditional autograft techniques. Sheep subjects underwent lateral lumbar fusion surgery using either PEEK or Titanium interbody cages packed with varying dosages of OsteoAdapt SP or autograft. Measures of success were assessed at intervals of eight, sixteen, and twenty-six weeks with techniques including CT and micro-CT analyses to evaluate new bone formation and fusion quality.
Notably, the results indicated that the adhesive variant of BMP-2, AMP2, facilitated bone healing outcomes equivalent to or better than traditional autograft methods. The precise delivery method reduced the risks often associated with BMP-2 treatments, further enhancing the therapeutic potential of OsteoAdapt SP.
Future Directions and Clinical Trials
With the preclinical study's success, Theradaptive is actively enrolling patients in its Phase I/II clinical trial, known as OASIS, to further assess OsteoAdapt SP's safety and efficacy for patients dealing with degenerative lumbosacral diseases. This advancement signifies not only a promising solution for addressing severe spinal conditions but also endeavors to meet the substantial unmet medical needs of many patients.
About Theradaptive
Theradaptive stands as a leader in developing targeted protein therapeutics aimed at revolutionizing treatment in fields such as spine care, orthopedics, and immuno-oncology. Based in Frederick, Maryland, the company utilizes a unique therapeutic delivery platform designed to administer recombinant biologics directly to tissues, ensuring high precision and efficacy.
Frequently Asked Questions
What is OsteoAdapt SP?
OsteoAdapt SP is an investigational therapeutic developed by Theradaptive for treating degenerative disc disease, enhancing bone formation while mitigating side effects of traditional treatments.
How does OsteoAdapt SP work?
It combines a modified version of BMP-2 with a synthetic bone graft to promote faster and more reliable bone healing.
What were the key results from the preclinical study?
The study showed that OsteoAdapt SP outperformed traditional autograft techniques in terms of bone formation speed and quality.
Is Theradaptive conducting clinical trials?
Yes, Theradaptive is currently enrolling patients in its OASIS Phase I/II clinical trial to evaluate OsteoAdapt SP's efficacy and safety.
Where can I learn more about Theradaptive?
For additional details on Theradaptive and its innovative products, please visit their official website or follow them on LinkedIn.
